HUT77127A - Pharmaceutical preparation for ovarian tonic estrogen secretion for long-term treatment - Google Patents

Pharmaceutical preparation for ovarian tonic estrogen secretion for long-term treatment

Info

Publication number
HUT77127A
HUT77127A HU9700046A HU9700046A HUT77127A HU T77127 A HUT77127 A HU T77127A HU 9700046 A HU9700046 A HU 9700046A HU 9700046 A HU9700046 A HU 9700046A HU T77127 A HUT77127 A HU T77127A
Authority
HU
Hungary
Prior art keywords
tonic
ovarian
long
pharmaceutical preparation
term treatment
Prior art date
Application number
HU9700046A
Other languages
Hungarian (hu)
Other versions
HU218910B (en
HU9700046D0 (en
Inventor
Gary D. Hodgen
Audrey Philips
Original Assignee
Ortho Pharmaceutical Corporation
The Medical College Of Hampton Roads
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUT77127(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by Ortho Pharmaceutical Corporation, The Medical College Of Hampton Roads filed Critical Ortho Pharmaceutical Corporation
Publication of HU9700046D0 publication Critical patent/HU9700046D0/en
Publication of HUT77127A publication Critical patent/HUT77127A/en
Publication of HU218910B publication Critical patent/HU218910B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
HU9700046A 1994-07-22 1995-07-18 Use of gonadotropin-releasing-hormone-antagonist polypeptids for producing pharmaceurical compositions for treatment gonodal-steroid conditions in mammals HU218910B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (3)

Publication Number Publication Date
HU9700046D0 HU9700046D0 (en) 1997-02-28
HUT77127A true HUT77127A (en) 1998-03-02
HU218910B HU218910B (en) 2000-12-28

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9700046A HU218910B (en) 1994-07-22 1995-07-18 Use of gonadotropin-releasing-hormone-antagonist polypeptids for producing pharmaceurical compositions for treatment gonodal-steroid conditions in mammals

Country Status (29)

Country Link
EP (1) EP0769956B1 (en)
JP (1) JP3138477B2 (en)
CN (1) CN1137722C (en)
AP (1) AP775A (en)
AT (1) ATE190494T1 (en)
AU (1) AU691952B2 (en)
BG (1) BG63363B1 (en)
BR (1) BR9508718A (en)
CA (1) CA2195745C (en)
CY (1) CY2228B1 (en)
CZ (1) CZ291803B6 (en)
DE (1) DE69515666T2 (en)
DK (1) DK0769956T3 (en)
EE (1) EE03515B1 (en)
ES (1) ES2145286T3 (en)
FI (1) FI970244L (en)
GR (1) GR3033590T3 (en)
HU (1) HU218910B (en)
IL (1) IL114655A (en)
IS (1) IS4413A (en)
LV (1) LV11823B (en)
MX (1) MX9700574A (en)
NO (1) NO970257L (en)
NZ (1) NZ290554A (en)
OA (1) OA10730A (en)
PT (1) PT769956E (en)
RU (1) RU2181598C2 (en)
SK (1) SK282118B6 (en)
WO (1) WO1996003138A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
NZ534836A (en) * 1999-09-23 2007-07-27 Zentaris Gmbh Method for the therapeutic management of extrauterine proliferatoin of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
DE10137174A1 (en) * 2001-07-31 2003-02-13 Zentaris Ag Use of LHRH antagonists in non-castrating doses to improve T cell-mediated immunity
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
HUE047732T2 (en) * 2015-05-18 2020-05-28 Nerre Therapeutics Ltd NK-1 / NK-3 receptor antagonist for the treatment of congestion
PL3765024T3 (en) 2018-03-14 2024-08-05 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists.
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
CN1200674A (en) 1998-12-02
NO970257D0 (en) 1997-01-21
HU218910B (en) 2000-12-28
NO970257L (en) 1997-01-21
JP3138477B2 (en) 2001-02-26
JPH10503203A (en) 1998-03-24
IL114655A0 (en) 1995-11-27
NZ290554A (en) 2000-08-25
PT769956E (en) 2000-07-31
LV11823A (en) 1997-08-20
AP775A (en) 1999-10-28
CZ291803B6 (en) 2003-06-18
CY2228B1 (en) 2003-04-18
CZ15097A3 (en) 1997-11-12
FI970244A7 (en) 1997-01-21
LV11823B (en) 1998-03-20
FI970244A0 (en) 1997-01-21
IS4413A (en) 1997-01-14
CN1137722C (en) 2004-02-11
HU9700046D0 (en) 1997-02-28
AP9700913A0 (en) 1997-01-31
MX9700574A (en) 1997-12-31
WO1996003138A1 (en) 1996-02-08
SK7097A3 (en) 1997-11-05
AU691952B2 (en) 1998-05-28
RU2181598C2 (en) 2002-04-27
EP0769956A4 (en) 1999-03-10
GR3033590T3 (en) 2000-09-29
CA2195745A1 (en) 1996-02-08
IL114655A (en) 2005-08-31
EP0769956B1 (en) 2000-03-15
OA10730A (en) 2001-06-07
EE9700208A (en) 1998-02-16
ATE190494T1 (en) 2000-04-15
BG101158A (en) 1997-09-30
AU3132095A (en) 1996-02-22
EE03515B1 (en) 2001-10-15
EP0769956A1 (en) 1997-05-02
DE69515666T2 (en) 2000-07-06
SK282118B6 (en) 2001-11-06
ES2145286T3 (en) 2000-07-01
CA2195745C (en) 2005-03-29
DK0769956T3 (en) 2000-06-05
BR9508718A (en) 1997-12-30
BG63363B1 (en) 2001-11-30
FI970244L (en) 1997-01-21
DE69515666D1 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
DK0785792T3 (en) Preparation for the treatment of ovarian estrogen dependent diseases
NO965343L (en) For containing herbal medicine
ATE226819T1 (en) MEDICINAL PREPARATIONS FOR PIPERIDINE CANOLDER DERIVATIVES
ID16038A (en) PHARMACEUTICAL COMPOSITION FOR IMMUNOMODULATION
NO965539D0 (en) Pharmaceutical tacrine preparations
FI971018L (en) Pharmaceutical compounds
ATE178489T1 (en) LIQUID ORAL MEDICINAL PREPARATIONS CONTAINING PAROXETINE RESINATE
ATE187063T1 (en) DRUG
IS4374A (en) Valve for inhaler
FI945441L (en) A new method for the preparation of 7beta-substituted-4-aza-5alpha-androstan-3-ones
DE69530614D1 (en) IONTOPHORESE PLASTER
FI954243A7 (en) Pharmaceutical compounds
GB9408053D0 (en) Pharmaceutical preparation
FI20001776A7 (en) Method for preparing a pharmaceutical composition
IS5062A (en) Medicinal preparations containing N-sulfonylindoline derivatives
FI913554L (en) Method for preparing a stabilized pharmaceutical composition
FI970564L (en) A new method for the preparation of diisopinocampheylchloroborane
FI970244A0 (en) Procedure for stabilizing the secretion of tonic ovarian estrogen for continued care
FI964436A7 (en) Novel hydroxime derivatives, pharmaceutical compositions containing them and a method for their preparation
FI951155A7 (en) Pharmaceutical preparation
FI944460A0 (en) Method for preparing a pharmaceutical preparation
LV11026A (en) A pharmaceutical composition for lowering blood pressure and retarding it
LT97021A (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
EE200000401A (en) Process for the preparation of a pharmaceutical preparation
DE69524720D1 (en) DERMATOLOGICAL PREPARATIONS

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees